Get started
Author

Inge M.W. Verberk

Observed names: I.M.W. Verberk, Inge M W Verberk, Inge M. W. Verberk, Inge MW Verberk, Inge Verberk, Verberk, I., Verberk, I. M. W., Verberk, Inge M W, Verberk, Inge M. W., Verberk, Inge M.W., Verberk, Inge M.W. (Dr. rer. nat.), Verberk, Inge MW, Verberk, Inge Maria Wilhelmina
Observed institutions: Karolinska Institutet, Maastricht University, Amsterdam Neuroscience, Amsterdam University Medical Centers, University College London, Vrije Universiteit Amsterdam, University of Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
ORCID: 0000-0003-0341-7445
Observed ORCID: 0000-0003-0341-7445
OpenAlex ID: A5064543445
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
2021 · Shorena Janelidze, Charlotte E. Teunissen, et al. · JAMA Neurology · 493
PDF
Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
2021 · Pratishtha Chatterjee, Steve Pedrini, et al. · Translational Psychiatry · 437
PDF
Plasma Amyloid as Prescreener for the Earliest A lzheimer Pathological Changes
2018 · Inge M. W. Verberk, Rosalinde E. Slot, et al. · Annals of Neurology · 315
PDF
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
2020 · Inge M. W. Verberk, Elisabeth Thijssen, et al. · Alzheimer s Research & Therapy · 258
PDF
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
2021 · Inge M. W. Verberk, Els O. Misdorp, et al. · Alzheimer s & Dementia · 238
Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study
2021 · Inge M W Verberk, Malika B Laarhuis, et al. · The Lancet Healthy Longevity · 202
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
2024 · Joseph Therriault, Suzanne E. Schindler, et al. · Nature Reviews Neurology · 198
ATN classification and clinical progression in subjective cognitive decline
2020 · Jarith L. Ebenau, Tessa Timmers, et al. · Neurology · 191
PDF
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
2021 · Sherif Bayoumy, Inge M. W. Verberk, et al. · Alzheimer s Research & Therapy · 190
PDF
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau
2021 · Shorena Janelidze, Sebastian Palmqvist, et al. · Alzheimer s & Dementia · 188
PDF
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study
2019 · Emma L van der Ende, Lieke H Meeter, et al. · The Lancet Neurology · 181
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
2024 · Michael Schöll, Inge M W Verberk, et al. · The Lancet Healthy Longevity · 136
Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface
2022 · Lisa Vermunt, Marco Otte, et al. · Annals of Clinical and Translational Neurology · 135
PDF
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis
2020 · Steffi De Meyer, Jolien M. Schaeverbeke, et al. · Alzheimer s Research & Therapy · 100
PDF
CSF or Serum Neurofilament Light Added to α‐Synuclein Panel Discriminates Parkinson's From Controls
2019 · Linda P. Oosterveld, Inge M.W. Verberk, et al. · Movement Disorders · 95
PDF
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
2022 · Elisabeth H. Thijssen, Inge M.W. Verberk, et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 86
PDF
Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
2021 · Elisabeth H. Thijssen, Inge M. W. Verberk, et al. · Scientific Reports · 86
PDF
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
2020 · Julia Stockmann, Inge M. W. Verberk, et al. · Alzheimer s Research & Therapy · 62
PDF
A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
2022 · Emma M. Coomans, Inge M.W. Verberk, et al. · Journal of Nuclear Medicine · 61
PDF
Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project
2020 · Inge M.W. Verberk, Heleen M.A. Hendriksen, et al. · Neurobiology of Aging · 56
PDF
Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
2023 · Charlotte E. Teunissen, Leighann Kimble, et al. · Molecular & Cellular Proteomics · 55
PDF
Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1
2022 · Zoë Y. G. J. van Lierop, Inge M. W. Verberk, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 53
The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases
2024 · Dea Gogishvili, Madison I. J. Honey, et al. · Journal of Neurochemistry · 47
PDF
Adaptive immune changes associate with clinical progression of Alzheimer’s disease
2024 · Lynn van Olst, Alwin Kamermans, et al. · Molecular Neurodegeneration · 47
Fully automated measurement of plasma Aβ42/40 and p‐tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
2024 · Giovanni Bellomo, Sherif Bayoumy, et al. · Alzheimer s & Dementia · 46
PDF
Works count: 211
Citation count: 4,782
H-index: 30
I10-index: 58
Year
Topic
Type